Dong-A Socio Holdings Continues Smooth Sailing This Year Following Record-Breaking Performance Last Year

Dong-A Socio Holdings continued its steady growth this year following its record-breaking performance last year.

Exterior view of Dong-A Socio Holdings headquarters building
[Photo by Dong-A Socio Holdings]

Dong-A Socio Holdings announced on the 25th that its consolidated financial statement for the second quarter showed provisional operating revenue of 324.491 billion KRW and operating profit of 22.311 billion KRW. Compared to the same period last year, revenue increased by 13.9% and operating profit by 13.7%.

For the first half of the year, revenue was 629.411 billion KRW and operating profit was 378.6 million KRW, representing increases of 16.46% and 4.87%, respectively, compared to the first half of last year. The company explained, "Revenue increased due to the expansion of major business subsidiaries," adding, "Operating profit rose thanks to profit improvements at Yongma Logistics and STGen Bio, despite a temporary increase in cost ratio caused by concentrated sales and administrative expenses in the first half for Dong-A Pharmaceutical’s annual sales growth, relocation of the head factory, and operation of the Dongcheon-su new plant."

Looking at the first half performance by major subsidiaries, healthcare specialist Dong-A Pharmaceutical saw growth across all business sectors, with the over-the-counter (OTC) drug segment leading the expansion. Revenue reached 334 billion KRW, up 9.4% year-on-year. Operating profit also increased slightly by 0.4% to 40.4 billion KRW. Among business segments, the OTC drug sector showed remarkable growth, with revenue rising by 12.6 billion KRW (16.9%) to 87.5 billion KRW compared to the same period last year. The Bacchus business segment increased by 2.7 billion KRW (2.2%), and the lifestyle health segment grew by 8.5 billion KRW (8.8%).

Biopharmaceutical specialist STGen Bio posted revenue of 19.2 billion KRW, a 19.1% increase. Operating profit turned positive at 400 million KRW, compared to an operating loss of 8.6 billion KRW in the same period last year. This performance growth was driven by increased sales of the Japanese commercialized product Nesp biosimilar and the upcoming global launch of the Stelara biosimilar in the second half of the year.

Logistics specialist Yongma Logistics recorded revenue of 193.3 billion KRW, up 13.7%. Operating profit surged 112.9% to 9.9 billion KRW. The company attributed the increases in both revenue and operating profit to new client acquisitions, growth in cosmetics logistics, and operational efficiency improvements.

Meanwhile, affiliates Dong-A ST and ST Pharm also announced their second-quarter results on the same day. Dong-A ST reported revenue of 157.7 billion KRW, a 2.3% increase year-on-year, but operating profit declined by 18.9% to 7.1 billion KRW.

ST Pharm posted revenue of 44.589 billion KRW, down 22.8% compared to the same period last year. Operating loss was 3.062 billion KRW, marking a return to the red.